Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Sells $20,139.00 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Adeoye Y. Olukotun sold 959 shares of the firm’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $21.00, for a total transaction of $20,139.00. Following the completion of the transaction, the director now owns 35,781 shares in the company, valued at $751,401. The trade was a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Arrowhead Pharmaceuticals Trading Down 0.4 %

Shares of ARWR stock opened at $19.95 on Thursday. The firm has a fifty day moving average of $20.81 and a 200-day moving average of $21.85. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -3.97 and a beta of 0.97. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $17.05 and a 52-week high of $36.72. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $38,000. Values First Advisors Inc. acquired a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at $52,000. Van ECK Associates Corp grew its position in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 788 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 1,644 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARWR. Citigroup dropped their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Sanford C. Bernstein dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, January 23rd. Chardan Capital reaffirmed a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $43.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.